Salvage HIFU for recurrent prostate cancer
This study assesses biological activity of two doses of pomegranate extract (POMx) in men with recurrent prostate cancer
, using changes in PSADT as the primary outcome.
and being studied in a pivotal FDA clinical trial as a possible treatment for recurrent prostate cancer
in patients treated previously with external beam radiation therapy; Sonablate 500 which has CE Marking and is, or has been, approved for use to treat prostate cancer in more than 30 countries outside the U.
Food and Drug Administration today approved the production and use of Choline C 11 Injection, a Positron Emission Tomography (PET) imaging agent used to help detect recurrent prostate cancer
No consensus on when and how to detect and cure radio recurrent prostate cancer
exists, but strong evidence indicates that salvage therapies may improve survival rates in patients with prostate cancer.
Study leader Dr William Figg, from the National Institutes of Health, in Bethesda, Maryland, US, said: "Thalidomide is associated with an increase in PSA progression-free survival in men with biochemically recurrent prostate cancer
after intermittent ADT.
the company sponsoring the clinical trial, different types of HIFU technology have been tested in clinical trials at Indiana University School of Medicine, Georgetown University Medical Center, Baylor College of Medicine, and the University of California San Francisco School of Medicine in men with recurrent prostate cancer
for whom radiation therapy failed.
5 years after treatment and complete regression of the recurrent prostate cancer
Chin and his group are to be commended for their ongoing assessment of salvage therapies in selected patients with recurrent prostate cancer
The Center for High Risk and Recurrent Prostate Cancer
401 East Las Olas Blvd.
In a study run by the Eastern Cooperative Oncology Group, the effect of PROSTVAC(TM) vaccination in patients with early stage recurrent prostate cancer
In a randomized phase III trial comparing thalidomide with placebo in patients with biochemically recurrent prostate cancer
after definitive therapy, thalidomide prolonged progression-free survival, as measured by changes in prostate-specific antigen (PSA) in patients with stage D0 disease, reported Dr.